| WHAT HAS CHANGED FROM THE ORIGINAL IMRALDI™ | |
|---|---|
 |
The volume of the solution in Imraldi™ pen or pre-filled syringe is lower due to the high concentration formulation – 0.4 ml instead of the previous 0.8 ml. |
 |
New formulation of Imraldi™ does not include citrate. |
 |
Imraldi™ has out of the fridge stability for 31 days at temperatures up to a maximum of 25°C.†1 This is an increase of 3 days as compared with the previous Imraldi™ formulation. |
 |
lnjection window in the Imraldi™ pen is now smaller and your lmraldi™ syringe is shorter. |
† The syringe or pen must be protected from light, and discarded if not used within the 31-day period.
| WHAT REMAINS THE SAME AS THE ORIGINAL IMRALDI | |
|---|---|
 |
One injection of Imraldi™ contains the same dose of the same active ingredient adalimumab. |
 |
The effectiveness of lmraldi™ remains comparable as it contains the same active ingredient. |
 |
Side effects due to the mode of action, as the active ingredient is still the same. |
 |
There is no change in the way your patient will administer the medicine. |
